7. Additional structural chromosomal abnormalities have a negative prognostic effect in patients with inv(16)/t(16;16) acute myeloid leukemia (AML)

This study included 264 inv(16)/t(16;16)/CBFB-MYH11 AML patients (M/F  = 148/116; median age: 49, range 2-89 years). During a median follow-up of 34 months (range 1-190 months), 82 patients died, 169 achieved a complete remission and 13 had a partial response. Among 234 patients with abnormal karyotype, 218 had inv(16)(p13q22) and 16 had t(16;16)(p13;q22); and 110 (47%) had inv(16)/t(16;16) as the sole abnormality (Group A), 72 (30.8%) had one additional abnormality (Group B), and 52 (22.2%) had two or more abnormalities (complex karyotype, Group C).

Source: Cancer Genetics and Cytogenetics - March 31, 2019 Category: Genetics & Stem Cells Authors: Zhenya Tang, Pei Zhao, Wei Wang, Jun Gu, Keyur P. Patel, Chi Y. Ok, Gokce A. Toruner, Joseph Khoury, L. Jeffrey Medeiros, Guilin Tang Source Type: research